NCT05815719

Continuous Double Ovarian Stimulation.

Continuous Ovarian Stimulation in DUOSTIM Cycles.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Instituto Bernabeu · Academic / Other
• Sex: Female
• Age: 18 Years – 43 Years
• Healthy volunteers: Accepted

Summary

To evaluate the efficacy of the weekly use of corifollitropin alfa in double ovarian stimulation process and to compare it to the conventional protocol with daily medication administration.

Detailed description

The purpose of this pilot study is to evaluate the efficacy of the weekly use of corifollitropin alfa in terms of ovarian stimulation results and its biological outcomes (total number of oocytes retrieved) in case of ovarian stimulation cycles in double stimulation modality (DUOSTIM) and in comparison with the conventional DUOSTIM protocol: daily administration of gonadotropins.

Conditions

• Fertility Issues

Interventions

Type	Name	Description
DRUG	Corifollitropin Alfa	150 micrograms per dose
DRUG	Follitropin Alfa	Variable dose.
DRUG	Follitropin Alfa Biosimilar	Variable dose.
DRUG	Urinary Human follicle stimulating hormone	Variable dose.

Timeline

• Start date: 2022-11-17
• Primary completion: 2023-04-30
• Completion: 2023-05-30
• First posted: 2023-04-18
• Last updated: 2025-05-18
• Results posted: 2025-05-18

Locations

1 site across 1 country: Spain